2025 Report on FDA Scientific Conferences With Expenses Over $30,000
21st Century Cures Act Reports on Scientific Conferences
Section 3074 of 21st Century Cures Act requires the FDA to report on scientific conferences hosted, sponsored, co-sponsored, or attendance at non-Federal Scientific Meetings with FDA expenses in excess of $30,000. The following outlines the total expenses for each scientific meeting together with other pertinent information including how the conference advanced the mission of the agency, a description of the conference activities. Section 3074 requires additional information of compelling circumstances for the costs exceeding $150,000.
2025 Annual Report
1. Compounding Quality Center of Excellence Annual Conference
Applicable Conference Type: FDA Hosted/Sponsored/Co-Sponsored
Conference Location: Rockville, Maryland
Conference Start Date: 08/27/2025
Conference End Date: 08/28/2025
Total FDA cost of the conference: $783,100.16
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 38
Explanation of how conference advanced the mission of FDA:
The Compounding Quality Center of Excellence Annual Conference advanced FDA’s mission by strengthening regulatory understanding and compliance within the outsourcing facility sector, which plays a critical role in the availability of compounded drugs for hospitals, clinics, and other healthcare providers. The conference supported FDA’s responsibility to oversee outsourcing facilities established under Section 503B of the Federal Food, Drug, and Cosmetic Act, a relatively young and evolving industry that has continued to experience quality and safety challenges, including a high rate of Official Action Indicated (OAI) inspection outcomes. Through targeted education and engagement, FDA used the conference to communicate statutory requirements, Current Good Manufacturing Practice (CGMP) expectations, and oversight approaches. FDA’s sponsorship enabled the Agency to maintain oversight of conference content and ensure that participants received accurate, consistent information aligned with FDA regulatory standards. By promoting shared understanding of regulatory expectations, the conference helped improve compliance, strengthen drug quality, and support patient access to safe and effective compounded medications.
General description of the scientific conference activities:
The Compounding Quality Center of Excellence Annual Conference was conducted as a year-end scientific and regulatory meeting for outsourcing facility staff, compounders interested in becoming outsourcing facilities, associated stakeholders, and federal and state regulators. The conference featured educational sessions and discussions focused on issues related to outsourcing facilities and compounded drug production. Attendees engaged directly with FDA subject-matter experts and participated in sessions addressing emerging trends in compounding practices, quality challenges, and best practices. Conference programming included presentations and discussions relevant to Section 503B requirements, CGMP compliance under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act, and issues related to patient access to medications. The conference also facilitated engagement among industry members and regulators, supporting professional networking and fostering a shared understanding of regulatory expectations. All sessions were aligned with FDA’s regulatory framework and oversight priorities for outsourcing facilities.
Explanation/description of circumstances for conference exceeding $150,000:
The U.S. Food and Drug Administration (FDA) is responsible for protecting the public health by
assuring the safety, efficacy and security of human and veterinary drugs, biological products,
medical devices, the nation’s food supply, cosmetics and products that emit radiation. The FDA is also responsible for advancing the public health by helping to speed innovations that make
biologics, medicines, and foods more effective, safer, and more affordable; and helping the public access accurate science-based information for drug products and foods. The FDA’s mission is to ensure the safety purity, potency, and effectiveness of regulated products. The agency is committed to providing the public with accurate, timely and easy to understand information on agency policies, programs, and actions.
The Center for Drug Evaluation and Research’s (CDER) mission is to protect and promote public
health by helping to ensure that human drugs are safe and effective for their intended use, meet established quality standards and are available to patients.
CDER’s Office of Compliance (OC) plays a critical role in protecting and promoting public health by shielding patients from poor quality, unsafe and ineffective drugs. The complexity of the human drug supply and development pipeline and the global nature of the regulated industry present unprecedented challenges to effective regulatory oversight. CDER’s Office of Compliance encompasses seven offices who collectively support FDA’s overall mission:
- Office of Manufacturing Quality (OMQ)
- Office of Compounding Quality Compliance (OCQC)
- Office of Unapproved Drug Labeling and Compliance (OUDLC)
- Office of Drug Security, Integrity and Response (ODSIR)
- Office of Scientific Investigations (OSI)
- Office of Program and Regulatory Operations (OPRO)
- Program Management and Analysis Staff (PMAS)
CDER’s Office of Compliance, as well as other offices in CDER (such as the Office of Pharmaceutical Quality) and other offices at the FDA (such as the Office of Regulatory Affairs) work together to advance FDA’s work related to drug compounding.
Drug compounding is generally the practice of combining, mixing, or altering ingredients of a drug or active pharmaceutical ingredient (bulk drug substance) to create a medication tailored to the needs of an individual patient. Although compounded drugs can serve an important medical need for certain patients when an approved drug is not medically appropriate, they also present a risk to patients. Compounded drugs are not FDA-approved. Therefore, they do not undergo premarket review by FDA for safety, effectiveness, and quality. Since compounded drugs are subject to a lower regulatory standard than approved drugs, Federal law places conditions on compounding that are designed to protect the public health.
The Drug Quality and Security Act of 2013 created “outsourcing facilities” – a new industry sector of drug compounders held to higher quality standards to protect patient health. Outsourcing facilities are intended to offer a more reliable supply of compounded drugs needed by hospitals, clinics, and other providers. Seven years since its creation, this domestic industry is still relatively small (approximately 75 entities) and is experiencing growth and market challenges. FDA continues to find challenges concerning drug quality and safety during inspections.
To help this industry meet its intended function, FDA formed the Compounding Quality Center of Excellence (COE) in fall 2019 to engage in a number of initiatives to address challenges and support advancement. One initiative includes holding an annual conference for the outsourcing facilities and associated stakeholders to learn and engage on emerging trends and compounding best practices. To date, the COE has held five annual conferences, with a sixth planned for 2025. These conferences have been very well attended and are highly rated by attendees.
There were over 950 attendees for the 2024 conference including outsourcing facilities and associated stakeholders such as: federal and state regulators, pharmacy organizations, professional organizations, hospital and health systems, patient organizations, suppliers, and regulatory consultants. This is the only existing large-scale meeting centered on outsourcing facility issues and has become a mainstay within the compounding community over its five years of existence. It enables outsourcing facilities to engage with FDA and other stakeholders and learn about emerging trends and compounding best practices to better adhere to statutory mandates and improve the quality of compounded drugs that outsourcing facilities produce.
2. Small Business Regulatory Education for Industry Generic Drugs Forums
Applicable Conference Type: FDA Hosted/Sponsored/Co-Sponsored
Conference Location: Rockville, Maryland
Conference Start Date: 04/09/2025
Conference End Date: 04/10/2025
Total FDA cost of the conference: $159,108.14
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 40
Explanation of how conference advanced the mission of FDA:
The Small Business Regulatory Education for Industry Generic Drugs Forums advanced FDA’s mission by supporting the Center for Drug Evaluation and Research’s (CDER) efforts to promote timely, high-quality development and regulation of generic drug products. The conference aligned with the mission of CDER’s Small Business and Industry Assistance (SBIA) program to foster productive interactions with regulated domestic and international small pharmaceutical businesses. By educating industry participants on key elements of the generic drug development continuum, the forum helped improve regulatory understanding and compliance, enabling sponsors to submit more complete and higher-quality applications. FDA’s engagement through this program supported first-cycle approvals and contributed to more efficient review processes. The meeting also provided FDA with direct insight into industry questions and concerns regarding regulatory procedures, informing ongoing outreach and communication strategies and strengthening FDA’s ability to support public health through effective oversight of generic drug development.
General description of the scientific conference activities:
The Small Business Regulatory Education for Industry Generic Drugs Forums were conducted as a two-day hybrid scientific and regulatory education event for members of the pharmaceutical industry. The conference was a major program element of the CDER Small Business and Industry Assistance (SBIA) program within the Division of Drug Information in the CDER Office of Communications. Conference activities included presentations and interactive discussions focused on key aspects of the generic drug development continuum and FDA regulatory requirements. FDA staff worked closely with CDER’s Office of Generic Drugs to deliver targeted regulatory information to attendees. The forum facilitated direct dialogue between FDA and industry participants, allowing FDA to address questions and concerns related to regulatory procedures. While the conference targeted small pharmaceutical businesses, it was attended by participants from small, medium, and large companies with varying levels of regulatory experience.
Explanation/description of circumstances for conference exceeding $150,000:
The Generic Drugs Forum is an annual, two-day event that offers attendees the opportunity to hear from FDA subject matter experts from every part of the pre-ANDA program and ANDA assessment program. The goal of the forum is to provide practical regulatory information to aid prospective applicants in submitting complete and high-quality applications to maximize the efficiency and utility of each assessment cycle, with the intent to reduce the number of assessment cycles and facilitate timely access to safe, effective, and high-quality generic medicines. This year’s theme is Regulatory Considerations to Enhance Generic Drug Access, and our agenda will address essential regulatory information on how to engage with the Agency and gain information about ANDA development and ANDA assessment. Presentations will focus on resources, best practices, common deficiencies, and opportunities to engage with the Agency from pre-ANDA to post-approval submissions. The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance’s (SBIA’s) mission is to promote productive interaction by assisting regulated domestic and international small pharmaceutical business and industry seeking timely and accurate information relating to development and regulation of human drug products. SBIA outreach activities include hosting events in locations that have been determined to be geographically dense with small pharmaceutical businesses, including the generic drug, device, and biotechnology industries. CDER SBIA helps empower small businesses in their interactions with FDA and aids those businesses in the development of more complete submissions and first-cycle drug approvals. SBIA events target small pharmaceutical/devices/biologics business but in fact are widely attended by all levels of industry including small, medium, and large pharma with attendees exhibiting varied levels of expertise.
3. International Council for Harmonisation Montreal Meeting
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Montreal, Canada
Conference Start Date: 11/05/2024
Conference End Date: 11/06/2024
Total FDA cost of the conference: $139,696.07
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 47
Explanation of how conference advanced the mission of FDA:
The International Council for Harmonisation (ICH) Montreal Meeting advanced FDA’s mission by supporting international regulatory harmonization to ensure that safe, effective, and high-quality medicines were developed, registered, and maintained efficiently across global markets. As a Founding Regulatory Member of ICH, FDA played a central role in the development and advancement of harmonized technical guidelines that improved global drug development, manufacturing standards, and regulatory convergence. FDA participation supported regulatory reliance and resilience, particularly during global public health emergencies. FDA representatives provided the Agency’s scientific and regulatory perspective in expert discussions addressing complex and novel technical issues related to drug safety, efficacy, quality, and electronic standards. Participation in expert working groups, including leadership on the ICH E21 guideline addressing inclusion of pregnant and breastfeeding individuals in clinical trials, was essential to advancing internationally harmonized regulatory standards aligned with FDA’s public health mission.
General description of the scientific conference activities:
The ICH Biannual Meeting in Montreal was conducted as an in-person international scientific and regulatory meeting for a limited number of expert working groups identified by the ICH Management Committee as requiring face-to-face engagement to address complex technical issues and advance guideline development. The meeting included sessions of the ICH Assembly, ICH Management Committee, ICH MedDRA Management Committee, and multiple ICH technical expert working groups. Discussions addressed a range of topics, including drug safety, efficacy, quality, and electronic standards. FDA participants served as speakers and panelists, contributed regulatory expertise, and exchanged information on FDA regulations, including areas such as cell and gene therapy drug development. The meeting also coincided with the International Pharmaceutical Regulators Programme (IPRP), enabling broader international regulatory engagement. No registration fees were charged, as attendees participated only on the days they were scheduled to speak. While most FDA attendees participated in person, one participant attended virtually.
4. American Association of Pharmaceutical Scientists PHARMSCI 360
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Salt Lake City, Utah
Conference Start Date: 10/20/2024
Conference End Date: 10/23/2024
Total FDA cost of the conference: $134,325.25
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 43
Explanation of how conference advanced the mission of FDA:
Attendance at the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 Conference advanced FDA’s mission by strengthening scientific expertise in discovery, basic research, and applied pharmaceutical sciences that underpin regulatory review, inspection, and oversight. The conference provided exposure to cutting-edge research, emerging technologies, and innovative methodologies relevant to drug development, manufacturing, bioanalytics, and quality analytics, including areas such as cell and gene therapy products. Participation helped address knowledge gaps in rapidly evolving scientific fields that directly impact FDA’s ability to evaluate safety, efficacy, and quality of regulated products. The meeting also supported FDA’s role in advancing regulatory science by enabling exchange of FDA regulatory perspectives, contributing to discussions on biomarkers, translational research, system pharmacology, pharmacogenomics, and modeling and simulation approaches relevant to regulatory decision-making under the Federal Food, Drug, and Cosmetic Act. Engagement with academia and industry strengthened collaborations, informed future training efforts, and supported regulatory reliance and resilience during public health needs, thereby enhancing FDA’s ability to protect public health through science-based regulation.
General description of the scientific conference activities:
PharmSci 360 was conducted as a large, multidisciplinary scientific conference that combined broad programming with focused, track-based engagement. The conference featured six scientific tracks, with balanced coverage of chemical and biomolecule drug development, allowing participants to engage deeply within a single track or move across tracks for a multidisciplinary perspective. Conference activities included scientific sessions with presentations by leading researchers and experts, hundreds of poster presentations highlighting emerging research, and partner presentations focused on practical science and best practices. Programming addressed discovery and basic research, biomarkers, translational science, bioanalytics innovations, quality analytics, system pharmacology, modeling and simulation, and pharmacogenomics. FDA participants contributed by presenting, moderating sessions, serving on panels, and exchanging regulatory information related to pharmaceutical science and bioanalytical innovation. The conference also provided opportunities for professional networking and collaboration, facilitating dialogue between FDA, academia, and industry on emerging scientific and regulatory issues.
5. American Society of Hematology Annual Meeting and Exposition
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: San Diego, California
Conference Start Date: 12/07/2024
Conference End Date: 12/10/2024
Total FDA cost of the conference: $111,256.24
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 33
Explanation of how conference advanced the mission of FDA:
Attendance at the American Society of Hematology (ASH) Annual Meeting and Exposition supported the FDA mission by strengthening the agency’s understanding of emerging scientific, clinical, and regulatory challenges related to blood diseases and oncology. Participation enabled FDA staff to stay current on advances in hematological research, diagnostics, and therapeutic development that directly inform regulatory review and oversight responsibilities. Engagement with clinicians, researchers, industry representatives, and patient advocates facilitated meaningful exchange of information relevant to evaluating safety, effectiveness, and quality of medical products. The conference also provided opportunities for FDA to share regulatory perspectives through panels and discussions, supporting transparency and mutual understanding with stakeholders. Overall, attendance enhanced FDA’s ability to protect and promote public health by ensuring regulatory decisions remained informed by the latest scientific evidence and evolving clinical practices.
General description of the scientific conference activities:
The American Society of Hematology Annual Meeting and Exposition functioned as a large, international scientific conference bringing together clinicians, scientists, industry representatives, advocates, and government participants focused on blood diseases and related cancers. The multi-day program featured hundreds of structured scientific and educational sessions covering cutting-edge research, clinical advances, and emerging issues in hematology. Attendees participated in presentations, panel discussions, and networking activities designed to foster collaboration and information exchange across disciplines. The conference also included an exposition with numerous exhibitors showcasing new treatments, diagnostic tools, and technologies relevant to hematological care and research. Through these activities, the meeting provided a comprehensive forum for discussing current challenges, innovations, and future directions in hematology and oncology.
6. American Society of Clinical Oncology Annual Meeting
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Chicago, Illinois
Conference Start Date: 05/30/2025
Conference End Date: 06/03/2025
Total FDA cost of the conference: $90,275.09
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 75
Explanation of how conference advanced the mission of FDA:
Attendance at the American Society of Clinical Oncology Annual Meeting supported the FDA’s mission by enabling agency staff to remain informed of the latest clinical, scientific, and technological advances in oncology research and cancer care. The meeting provided a critical forum for engaging with global oncology stakeholders, including clinicians, researchers, and industry representatives, allowing for the exchange of information on emerging trends that directly influence regulatory decision-making. Participation supported the FDA’s oversight responsibilities by enhancing understanding of innovations in clinical trial design, artificial intelligence applications, and oncology drug development across the product lifecycle. Engagement in structured scientific discussions and presentations strengthened the agency’s ability to anticipate regulatory challenges, evaluate novel methodologies, and promote science-based regulatory approaches. Overall, attendance enhanced the FDA’s capacity to protect public health by supporting informed, timely, and rigorous evaluation of oncology products and clinical research advancements.
General description of the scientific conference activities:
The American Society of Clinical Oncology Annual Meeting served as a large-scale, international scientific conference bringing together oncology professionals from academia, clinical practice, industry, and regulatory organizations. The meeting featured structured scientific sessions, panel discussions, and presentations addressing advances in cancer research, clinical trial innovation, and emerging technologies. Conference programming included focused discussions on the application of artificial intelligence to oncology clinical trials, including improving patient recruitment, enhancing diversity and accessibility, optimizing trial design, and assessing safety and effectiveness outcomes. FDA participation included presenting a regulatory perspective on the use of artificial intelligence across the oncology drug development continuum and engaging in panel discussions with other experts. The conference also provided opportunities for virtual participation, allowing broader engagement with scientific content and stakeholder discussions while supporting global collaboration and knowledge exchange within the oncology community.
7. American Public Health Association Annual Meeting and Expo
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Minneapolis, Minnesota
Conference Start Date: 10/27/2024
Conference End Date: 10/30/2024
Total FDA cost of the conference: $89,375.56
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 51
Explanation of how conference advanced the mission of FDA:
Attendance at the American Public Health Association Annual Meeting and Expo advanced the FDA’s mission by supporting engagement with national and international public health stakeholders on issues directly related to tobacco use prevention, health equity, and public health protection. The conference provided an annual opportunity for FDA staff to interact with federal partners, non-governmental organizations, and public health professionals whose work aligns with the agency’s efforts to reduce harms associated with tobacco use and other public health threats. Participation enabled attendees to gain insight into current research, stakeholder perspectives, and emerging public health issues, which informed FDA regulatory activities, communications, and public education efforts. The meeting also supported agency objectives by facilitating dialogue with organizations and individuals engaged in prevention and cessation initiatives and by strengthening relationships that advance FDA’s strategic public health priorities. Overall, attendance enhanced the agency’s ability to incorporate stakeholder feedback, strengthen advisory processes, and support evidence-based public health decision-making.
General description of the scientific conference activities:
The American Public Health Association Annual Meeting and Expo was a large, multi-day scientific and professional conference that convened the public health community to share best practices, research findings, and emerging trends across a wide range of public health disciplines. The conference featured structured educational sessions, scientific presentations, and an exposition showcasing public health initiatives, programs, and resources. Programming addressed topics such as tobacco regulation, health equity, public health research, and prevention strategies, providing attendees with opportunities to learn from experts and engage in discussions on pressing public health challenges. FDA participation included attending scientific sessions, engaging with stakeholders, and participating in outreach activities aimed at increasing awareness of agency initiatives and recruiting consumer representatives for advisory committees. The conference also served as a platform for networking, collaboration, and information exchange among public health professionals from across the United States and internationally.
8. Generics and Biosimilars Conference
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Rockville, Maryland
Conference Start Date: 10/21/2024
Conference End Date: 10/23/2024
Total FDA cost of the conference: $68,000.00
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 85
Explanation of how conference advanced the mission of FDA:
Attendance at the Generics and Biosimilars Conference advanced the FDA’s mission by supporting informed oversight of the generic and biosimilar drug markets and strengthening understanding of evolving scientific, regulatory, and policy issues affecting drug development, approval, and competition. Participation enabled FDA staff to remain current on emerging innovations, market trends, and policy developments within the generics and biosimilars sectors, which are critical to ensuring patient access to safe, effective, and affordable medicines. The conference provided valuable insight into regulatory challenges, approval pathways, and policy considerations that inform FDA decision-making related to generic drug development and pricing. Engagement with subject-matter experts and stakeholders supported the agency’s ability to anticipate industry trends, address regulatory complexities, and contribute to science-based policy development. Overall, attendance enhanced FDA’s capacity to promote a competitive marketplace while maintaining rigorous standards for drug quality, safety, and effectiveness.
General description of the scientific conference activities:
The Generics and Biosimilars Conference was a structured scientific, regulatory, and policy meeting focused on the U.S. generics and biosimilars industry. The conference featured keynote presentations and breakout sessions led by regulatory experts and industry leaders addressing current scientific developments, regulatory processes, and policy issues impacting generic and biosimilar drug development and approval. Programming covered topics such as regulatory pathways, evolving policy frameworks, technical considerations, and market dynamics within the generics and biosimilars space. The conference also included networking opportunities that facilitated professional engagement and information exchange among attendees with experience in regulatory science, policy, and industry practices. These activities supported knowledge sharing and collaboration relevant to FDA’s regulatory and public health responsibilities.
9. Association for the Advancement of Blood and Biotherapies Annual Meeting
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Houston, Texas
Conference Start Date: 10/19/2024
Conference End Date: 10/22/2024
Total FDA cost of the conference: $66,315.66
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 24
Explanation of how conference advanced the mission of FDA:
Attendance at the Association for the Advancement of Blood and Biotherapies Annual Meeting advanced the FDA’s mission by supporting oversight of blood and biotherapy safety, quality, and effectiveness. The conference provided FDA staff with access to the latest scientific, clinical, and operational developments in transfusion medicine and biotherapies, which informed regulatory activities related to donor eligibility, product quality, and patient safety. Participation enabled engagement with domestic and international stakeholders, fostering a shared understanding of evolving practices, regulatory expectations, and quality management approaches. The meeting supported FDA’s role in promoting compliance and consistency across the regulated community by reinforcing uniform interpretation of laws and regulations governing blood and biotherapies. Overall, attendance strengthened the agency’s ability to protect public health by remaining informed of emerging risks, innovations, and best practices that impact donor and patient safety.
General description of the scientific conference activities:
The Association for the Advancement of Blood and Biotherapies Annual Meeting was an international scientific and professional conference focused on transfusion medicine and biotherapies. The conference featured structured educational sessions, workshops, and peer-to-peer discussions addressing laboratory, clinical, and administrative practices in the field. Programming included presentations on advances in blood center records management, donor behavior and its impact on product quality, transfusion efficacy, and quality management systems. The meeting provided opportunities for FDA staff to participate in workshops, review case studies, and engage in technical discussions with healthcare professionals and regulatory counterparts. These activities facilitated information exchange, professional development, and collaboration aimed at improving donor eligibility practices, strengthening compliance, and enhancing patient safety in transfusion medicine and biotherapies.
10. American College of Toxicology 45th Annual Meeting
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Austin, Texas
Conference Start Date: 11/17/2024
Conference End Date: 11/20/2024
Total FDA cost of the conference: $66,224.08
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 25
Explanation of how conference advanced the mission of FDA:
Attendance at the American College of Toxicology 45th Annual Meeting advanced the FDA’s mission by strengthening the agency’s scientific expertise in toxicological sciences that inform regulatory review and public health protection. Participation supported FDA’s ability to evaluate emerging methods and approaches in applied toxicology relevant to the assessment of product safety, including considerations applicable to cell and gene therapy products and tobacco product regulatory review. The conference enabled FDA staff to remain informed of evolving scientific strategies that may be proposed by regulated entities to assess or reduce health risks, thereby supporting evidence-based decision-making. Engagement with the scientific community facilitated the exchange of regulatory perspectives and enhanced understanding of how toxicological methods, biomarkers, and study designs inform risk assessment. Overall, attendance supported the agency’s goal of enhancing scientific knowledge development to ensure rigorous, science-based regulatory oversight and protection of public health.
General description of the scientific conference activities:
The American College of Toxicology 45th Annual Meeting was a scientific conference focused on the principles and applications of toxicological sciences. The meeting featured structured symposia, lectures, and scientific sessions led by experts in applied toxicology, including discussions on in vivo and ex vivo toxicology testing, pathology, biomarker development, and emerging study design approaches. Conference programming provided opportunities for FDA staff to engage in scientific discussions, review new research findings, and exchange information on regulatory considerations related to safety assessment and toxicological best practices. The meeting also facilitated interaction with researchers and regulatory counterparts, supporting knowledge exchange on current trends and critical thinking in toxicology that are directly relevant to assessing health risks and informing regulatory evaluations.
11. Parenteral Drug Association Pharmaceutical Microbiology Conference
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Washington, District of Columbia
Conference Start Date: 10/07/2024
Conference End Date: 10/09/2024
Total FDA cost of the conference: $54,848.79
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 57
Explanation of how conference advanced the mission of FDA:
Attendance at the Parenteral Drug Association Pharmaceutical Microbiology Conference advanced the FDA’s mission by strengthening scientific and regulatory expertise related to the microbiological manufacturing and oversight of parenteral drug products. Participation supported the agency’s ability to evaluate current and emerging microbiological practices that impact product quality, sterility assurance, and patient safety. The conference provided FDA staff with insight into the intersection of scientific innovation and regulatory compliance, supporting evidence-based regulatory review and consistent application of microbiology standards. Engagement with industry, academic, and regulatory stakeholders enhanced understanding of global manufacturing challenges and evolving expectations, contributing to improved oversight of pharmaceutical production. Overall, attendance supported the agency’s responsibility to ensure the safety, quality, and effectiveness of parenteral drug products through informed, science-based regulatory decision-making.
General description of the scientific conference activities:
The Parenteral Drug Association Pharmaceutical Microbiology Conference was a structured scientific and regulatory meeting focused on microbiological considerations in the manufacturing of parenteral pharmaceutical products. The conference featured plenary sessions, technical presentations, roundtable discussions, and question-and-answer panels addressing current industry developments, regulatory updates, and advances in pharmaceutical microbiology. Programming emphasized topics related to microbial control strategies, advanced microbiological techniques, compliance challenges, and future trends affecting the global pharmaceutical market. The meeting provided opportunities for FDA staff to engage directly with expert presenters and stakeholders, participate in technical discussions, and exchange perspectives on challenges and opportunities in pharmaceutical microbiology. These activities supported knowledge sharing and collaboration relevant to regulatory review, compliance oversight, and public health protection.
12. Advamed Medtech Conference
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Toronto, Canada
Conference Start Date: 10/15/2024
Conference End Date: 10/17/2024
Total FDA cost of the conference: $54,015.51
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 14
Explanation of how conference advanced the mission of FDA:
Attendance at the AdvaMed MedTech Conference advanced the FDA’s mission by supporting informed oversight of medical device innovation, regulatory science, and supply chain resilience. Participation enabled FDA staff to gain insight into industry priorities related to medical device development, regulatory submissions, and emerging technologies that directly affect patient safety and device effectiveness. Engagement with stakeholders enhanced understanding of critical issues such as medical device sterilization, global supply chain resilience, and evolving regulatory frameworks across international markets, supporting FDA’s efforts to ensure continued access to safe and effective medical devices. The conference also supported agency initiatives aimed at fostering collaboration among regulators, industry, and public health stakeholders to address complex challenges within the medical device ecosystem. Overall, attendance strengthened FDA’s ability to anticipate regulatory challenges, inform policy development, and promote innovation while safeguarding public health.
General description of the scientific conference activities:
The AdvaMed MedTech Conference was a large, international scientific and industry conference that convened medical device innovators, researchers, policymakers, and regulators. The conference featured structured sessions, panels, and discussions focused on patient engagement, clinical trial design, quantitative and methodological innovation, and regulatory considerations for medical device development. Programming addressed advances in medical devices, diagnostics, imaging, and digital health technologies, as well as global harmonization efforts, supply chain trends, and evolving regulatory requirements in international markets. The conference also provided opportunities for professional engagement and collaboration, including discussions on innovation, commercialization, and technology transfer related to medical device research. These activities facilitated information exchange and stakeholder engagement relevant to FDA’s regulatory, scientific, and public health responsibilities.
13. American Society of Health System Pharmacists Midyear Clinical Meeting and Exhibition
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: New Orleans, Louisiana
Conference Start Date: 12/08/2024
Conference End Date: 12/12/2024
Total FDA cost of the conference: $53,262.60
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 17
Explanation of how conference advanced the mission of FDA:
Attendance at the American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition advanced the FDA’s mission by strengthening pharmacy-related scientific and clinical expertise that supports regulatory oversight and public health protection. Participation enabled FDA pharmacists to engage with the largest global gathering of pharmacy professionals, enhancing understanding of emerging practices, innovations, and challenges in health-system pharmacy. The conference supported professional development relevant to the agency’s increasingly complex role in evaluating and overseeing pharmaceutical products and medication-use systems. Engagement in educational programming and professional exchange contributed to informed regulatory decision-making and reinforced FDA’s capacity to promote safe, effective, and appropriate use of medications. Overall, attendance supported the agency’s mission by ensuring FDA staff remained current on advances in pharmacy practice that directly impact patient safety and public health.
General description of the scientific conference activities:
The American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition was a large, international professional and scientific conference that convened pharmacy professionals and students from around the world. The conference featured structured educational symposia, scientific sessions, and an exhibition highlighting innovations, best practices, and emerging trends in pharmacy practice. Programming provided opportunities for FDA staff to participate in educational sessions focused on clinical pharmacy, medication management, and evolving healthcare delivery models. The meeting also facilitated professional engagement and information exchange among pharmacy experts, supporting knowledge sharing and collaboration relevant to regulatory science and public health responsibilities.
14. 39th Annual Meeting and PreConference Programs Society for Immunotherapy of Cancer
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Houston, Texas
Conference Start Date: 11/08/2024
Conference End Date: 11/10/2024
Total FDA cost of the conference: $50,950.80
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 21
Explanation of how conference advanced the mission of FDA:
Attendance at the Society for Immunotherapy of Cancer 39th Annual Meeting advanced the FDA’s mission by supporting regulatory and scientific engagement in the rapidly evolving field of cancer immunology and immunotherapy. Participation enabled FDA staff to engage with key stakeholders, including academic researchers, international regulators, industry representatives, and patient advocates, to exchange information on emerging scientific developments and regulatory considerations related to immune-oncology products. The conference supported informed regulatory review by enhancing understanding of current challenges and opportunities in the development of cancer immunotherapies, including drugs and biologics. Engagement in scientific discussions and stakeholder dialogue strengthened FDA’s ability to anticipate innovation trends, assess novel therapeutic approaches, and apply science-based regulatory frameworks. Overall, attendance supported the agency’s mission to protect human health by remaining informed of advances that directly impact oncology product evaluation and public health outcomes.
General description of the scientific conference activities:
The Society for Immunotherapy of Cancer 39th Annual Meeting and Pre-Conference Programs was a large, international scientific conference focused on cancer immunotherapy. The meeting convened leaders from academia, government, regulatory agencies, industry, and patient advocacy organizations to share research findings, best practices, and emerging trends in immuno-oncology. Conference programming included structured scientific sessions, symposia, and networking opportunities that facilitated discussion of immune-oncology drug and biologic development, translational research, and clinical application. The meeting provided a forum for scientific exchange, professional engagement, and collaboration among participants driving innovation in cancer immunotherapy. These activities supported knowledge sharing and dialogue relevant to regulatory science, research advancement, and public health protection.
15. American Academy of Ophthalmology Annual Meeting
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Chicago, Illinois
Conference Start Date: 10/18/2024
Conference End Date: 10/21/2024
Total FDA cost of the conference: $42,223.57
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 17
Explanation of how conference advanced the mission of FDA:
Attendance and participation at the American Academy of Ophthalmology Annual Meeting advanced the FDA’s mission by supporting CDRH and OTP regulatory, scientific, and policy activities related to ophthalmic devices and eye health. Participation enabled FDA staff to obtain and exchange up-to-date information on advances in ophthalmology that directly informed premarket regulatory consults, scientific evaluations, and patient-centered device development. Engagement with academia, professional organizations, industry, and other stakeholders strengthened FDA’s ability to remain current on emerging technologies, clinical trial challenges, safety signals, and innovation trends relevant to ophthalmic device regulation. Attendance also supported dissemination of FDA regulatory perspectives and reinforced collaboration necessary to protect and promote public health.
General description of the scientific conference activities:
The American Academy of Ophthalmology Annual Meeting was a large, international professional conference bringing together ophthalmology experts from academia, government, professional societies, and industry. The meeting featured structured educational sessions, scientific presentations, panel discussions, and collaborative forums focused on recent advances in ophthalmology, clinical practice, and medical device development. The conference provided opportunities to discuss challenges related to innovation, safety, and regulatory science in the ophthalmic space, enabling attendees to stay informed on breakthroughs and emerging issues impacting patient care and device regulation.
16. American Society of Tropical Medicine and Hygiene
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: New Orleans, Louisiana
Conference Start Date: 11/13/2024
Conference End Date: 11/17/2024
Total FDA cost of the conference: $41,965.29
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 17
Explanation of how conference advanced the mission of FDA:
Attendance at the American Society of Tropical Medicine and Hygiene Annual Meeting supported FDA’s mission by enhancing regulatory, scientific, and public health expertise related to tropical and emerging infectious diseases. The conference provided critical information on advancements in diagnosis, medical treatment, and medical countermeasures for diseases such as Zika, dengue, Ebola, COVID-19, and other emerging pathogens. Participation enabled FDA staff to gain a deeper understanding of evolving public health needs and scientific developments, which directly informed regulatory review of diagnostic devices and medical countermeasures, contributing to well-informed assessments that protect public health.
General description of the scientific conference activities:
The American Society of Tropical Medicine and Hygiene Annual Meeting was a multi-day international scientific conference featuring structured sessions, research presentations, and discussions addressing tropical medicine, emerging infectious diseases, and global public health challenges. The conference brought together scientists, clinicians, researchers, and public health professionals from around the world to share world-class research findings, clinical updates, and emerging issues related to infectious diseases. The meeting provided a forum for scientific exchange on vaccine platforms, diagnostics, and medical countermeasures relevant to FDA’s regulatory and research missions.
17. American Association for the Study of Liver Diseases Liver Meeting
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: San Diego, California
Conference Start Date: 11/15/2024
Conference End Date: 11/19/2024
Total FDA cost of the conference: $40,969.21
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 15
Explanation of how conference advanced the mission of FDA:
Attendance at the American Association for the Study of Liver Diseases Liver Meeting supported FDA’s mission by advancing scientific and clinical understanding of liver diseases, biliary tract disorders, and liver transplantation. The conference provided exposure to groundbreaking basic, translational, and clinical research that informed regulatory science and enhanced FDA staff’s ability to evaluate emerging therapies, diagnostics, and treatment approaches related to liver disease. Participation supported the agency’s responsibility to protect public health by ensuring regulatory decisions were informed by the most current scientific evidence and clinical practices.
General description of the scientific conference activities:
The AASLD Liver Meeting served as an international forum for the presentation and exchange of state-of-the-art research and clinical practices related to hepatology and liver transplantation. The conference included structured scientific sessions, expert presentations, and discussions addressing the full spectrum of liver disease, including hepatobiliary malignancies, metabolic pathways, and emerging innovations in patient care and disease management. Attendees engaged with peers to exchange perspectives, discuss evolving clinical challenges, and review the latest industry and academic advancements relevant to liver disease research and treatment.
18. Public Responsibility in Medicine and Research Annual Conference
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Seattle, Washington
Conference Start Date: 11/17/2024
Conference End Date: 11/20/2024
Total FDA cost of the conference: $39,556.10
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 12
Explanation of how conference advanced the mission of FDA:
Attendance at the Public Responsibility in Medicine and Research Annual Conference supported FDA’s mission by strengthening understanding of ethical, responsible, and high-quality research oversight practices related to human subjects research and animal care. The conference informed FDA staff of recent developments in research conduct, protections, and oversight, which are directly relevant to ensuring the safety, rights, and welfare of research participants. Participation enhanced the agency’s ability to evaluate research practices and oversight frameworks in support of public health and regulatory decision-making.
General description of the scientific conference activities:
The PRIM&R Annual Conference brought together stakeholders and institutional leaders involved in research oversight to address complex, current issues across the research enterprise. The conference included structured plenary sessions, educational presentations, and breakout discussions focused on human subjects research protections, ethical considerations, and emerging challenges in research oversight. Breakout sessions allowed for in-depth exploration of specific topics and collaborative discussion with peers. Conference content addressed the full research lifecycle, including issues such as reproducibility, translatability, and the oversight implications of emerging research technologies, including gene editing and data-driven research approaches.
19. Veterinary Medicinal Products International Cooperation on Harmonisation
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Amsterdam, Netherlands
Conference Start Date: 11/08/2024
Conference End Date: 11/15/2024
Total FDA cost of the conference: $38,222.16
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 10
Explanation of how conference advanced the mission of FDA:
Participation in the Veterinary Medicinal Products International Cooperation on Harmonisation (VICH) advanced the mission of FDA by supporting the development and implementation of internationally harmonized, science-based guidelines for veterinary medicinal products. As a founding regulatory member of VICH, FDA played a critical role in trilateral harmonization efforts with international regulatory counterparts, ensuring that U.S. regulatory perspectives were incorporated into global decision-making. Attendance enabled FDA to contribute directly to Steering Committee deliberations, which served as the decision-making body for VICH and addressed the development, revision, and implementation of harmonized technical guidelines that support the availability of safe, effective, and high-quality veterinary medicinal products. Participation strengthened international regulatory collaboration, improved information exchange, raised global awareness of VICH activities, and promoted the use of harmonized standards among both member and non-member countries. Engagement in the Steering Committee, VICH Forum, and associated expert working group meetings supported broader international involvement, advanced a One Health approach, and helped ensure veterinary medicinal products met high standards of quality, safety, and efficacy that protect public health, animal health and welfare, and the environment on a global scale.
General description of the scientific conference activities:
The VICH meeting consisted of Steering Committee sessions, a VICH Forum, and expert working group meetings focused on harmonization of technical requirements for the registration of veterinary medicinal products. The Steering Committee sessions brought together regulatory authorities and representative industry associations from participating countries and regions to make decisions related to the development and implementation of harmonized guidelines. The VICH Forum provided an opportunity for additional countries and regions to gain awareness of VICH activities and participate in discussions to support broader international harmonization efforts. Steering Committee members organized and led Forum discussions, and an expert working group on bioequivalence convened to address scientific and regulatory issues related to the development of a new guideline on biowaivers. These activities involved structured technical discussions to resolve outstanding issues, advance guideline development, and support continued progress toward international regulatory alignment. The in-person format enabled effective collaboration, leadership engagement, and scientific discussion necessary to advance complex technical work that could not be achieved through remote participation.
20. Infectious Disease Week
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Los Angeles, California
Conference Start Date: 10/16/2024
Conference End Date: 10/19/2024
Total FDA cost of the conference: $36,649.21
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 11
Explanation of how conference advanced the mission of FDA:
Attendance at Infectious Disease Week advanced the mission of FDA by ensuring that agency staff maintained current knowledge and technical proficiency in the rapidly evolving field of infectious diseases. Participation enabled FDA personnel to remain informed on state-of-the-art clinical care, translational research, basic science advancements, and emerging challenges in infectious diseases and healthcare epidemiology. The knowledge gained supported FDA’s role in protecting public health by strengthening scientific understanding relevant to infectious disease prevention, diagnosis, treatment, and regulatory decision-making. Engagement with leading experts and stakeholders enhanced FDA’s ability to apply the latest scientific evidence to its work, informed assessments related to infectious disease products and interventions, and supported evidence-based policy and regulatory activities aligned with the agency’s public health mission.
General description of the scientific conference activities:
Infectious Disease Week served as a premier scientific forum bringing together clinicians, investigators, infection prevention specialists, pharmacists, and researchers to present and discuss recent advances in infectious disease clinical care, research, and healthcare epidemiology. The conference featured comprehensive scientific programming, including presentations on original clinical, translational, and basic research, as well as timely reviews of emerging infectious disease challenges. As a joint annual meeting of multiple professional societies in infectious diseases and related disciplines, the event facilitated collaboration, professional exchange, and interdisciplinary learning. Attendees participated in educational sessions, scientific discussions, and networking opportunities designed to enhance technical expertise, support professional development, and foster shared understanding of current and future issues impacting patient care and public health.
21. American Association of Veterinary Laboratory Diagnosticians
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Nashville, Tennessee
Conference Start Date: 10/10/2024
Conference End Date: 10/16/2024
Total FDA cost of the conference: $35,855.00
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 12
Explanation of how conference advanced the mission of FDA:
Attendance at the American Association of Veterinary Laboratory Diagnosticians Annual Meeting advanced the mission of FDA by enabling agency staff to remain current on developments in the diagnosis of animal diseases and emerging unmet needs in animal agriculture. Participation strengthened FDA’s ability to identify and respond to emerging issues related to food and feed safety by providing timely scientific and regulatory information relevant to animal health and public health protection. Engagement with laboratory leaders and stakeholders enhanced collaboration, facilitated feedback on national laboratory network activities, and supported the exchange of information critical to surveillance, disease detection, and regulatory decision-making. The knowledge gained supported FDA’s role in safeguarding the food supply and protecting animal and human health by improving situational awareness of emerging animal disease threats and diagnostic challenges.
General description of the scientific conference activities:
The American Association of Veterinary Laboratory Diagnosticians Annual Meeting served as the largest professional gathering of veterinary diagnosticians, bringing together experts from federal and state animal health agencies, diagnostic laboratories, industry, academia, and research institutions. The conference featured plenary sessions, concurrent scientific sessions, and technical discussions focused on animal health, disease control and eradication, diagnostic advancements, and laboratory practices. Attendees participated in scientific presentations, information exchange, and networking opportunities designed to enhance diagnostic capabilities, share emerging scientific findings, and discuss evolving regulatory requirements and laboratory needs. The meeting provided a forum for collaboration and professional engagement across the animal health community, supporting continued advancement in veterinary diagnostics and surveillance.
22. San Antonio Breast Cancer Symposium
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: San Antonio, Texas
Conference Start Date: 12/10/2024
Conference End Date: 12/13/2024
Total FDA cost of the conference: $34,231.26
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 12
Explanation of how conference advanced the mission of FDA:
Attendance at the San Antonio Breast Cancer Symposium advanced FDA’s mission by supporting the agency’s role in protecting public health through increased awareness and understanding of current scientific and clinical developments related to breast cancer. The scientific content presented at the symposium addressed key issues relevant to the safety, effectiveness, and evaluation of oncology products used in the prevention, diagnosis, and treatment of breast cancer. Participation enabled FDA staff to remain informed of emerging research, evolving therapeutic approaches, and advances in experimental biology and translational science that directly inform regulatory review and oversight of oncology products. Exposure to current scientific evidence and expert perspectives strengthened the agency’s ability to assess product benefits and risks and to support sound, science-based regulatory decision-making in the oncology space.
General description of the scientific conference activities:
The San Antonio Breast Cancer Symposium was an international scientific meeting designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and treatment of breast cancer and premalignant breast disease. The scientific program included formal lectures by experts in clinical, translational, and basic research, as well as selected slide and poster presentations, scientific forums, and case-based discussions. The symposium brought together academic and private physicians, researchers, patient advocates, and other health care professionals involved in medical, surgical, gynecologic, and radiation oncology. The conference facilitated scientific exchange, dissemination of new research findings, and discussion of emerging trends and challenges in breast cancer research and clinical practice.
23. American Institute of Chemical Engineers Annual Meeting
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: San Diego, California
Conference Start Date: 10/27/2024
Conference End Date: 10/31/2024
Total FDA cost of the conference: $33,236.05
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 10
Explanation of how conference advanced the mission of FDA:
Attendance at the American Institute of Chemical Engineers Annual Meeting advanced FDA’s mission by strengthening scientific and technical expertise related to chemical engineering applications relevant to pharmaceutical manufacturing and translational medicine. Participation supported the agency’s ability to evaluate emerging manufacturing technologies, process development approaches, and innovation trends that impact the quality, safety, and reliability of medical products. Engagement with academic and industry experts enhanced FDA staff understanding of cutting-edge research and manufacturing practices, directly supporting informed regulatory review and oversight. The knowledge gained contributed to improved assessment of manufacturing processes, helping ensure that regulated products meet appropriate quality standards and ultimately benefiting public health.
General description of the scientific conference activities:
The AIChE Annual Meeting served as a premier educational forum for chemical engineers focused on innovation, research advancement, and professional development. The conference featured presentations and technical sessions led by academic and industry experts covering a wide range of topics, including cutting-edge research, emerging technologies, and growth areas such as translational medicine and pharmaceutical manufacturing process development. Attendees participated in scientific exchanges that highlighted new methodologies, manufacturing innovations, and applied chemical engineering research relevant to drug development and production. The meeting provided opportunities for professional interaction, technical learning, and exposure to advances shaping the future of chemical engineering and pharmaceutical manufacturing.
24. Society of Environmental Toxicology and Chemistry North America Annual Meeting
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Fort Worth, Texas
Conference Start Date: 10/20/2024
Conference End Date: 10/24/2024
Total FDA cost of the conference: $32,543.65
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 12
Explanation of how conference advanced the mission of FDA:
Attendance at the Society of Environmental Toxicology and Chemistry (SETAC) North America Annual Meeting advanced the mission of FDA by supporting the Agency’s ability to conduct scientifically sound, interdisciplinary evaluations of environmental impacts associated with regulated products and federal actions. Participation ensured FDA staff remained current on the latest scientific approaches required to fulfill responsibilities under the National Environmental Policy Act (NEPA), including evaluation of environmental transport, fate, effects, and risk of chemical substances. The conference provided critical information on emerging environmental issues, analytical techniques, and computational methods relevant to environmental contaminants such as metals, persistent organic pollutants, and micro- and nano-plastics. This knowledge directly supported FDA’s regulatory review activities by strengthening the scientific basis used to assess environmental impacts and risks. Attendance also facilitated engagement with experts across academia, industry, and government, helping maintain professional relationships essential to FDA’s environmental assessment and regulatory decision-making functions. Failure to attend would have diminished the Agency’s efficiency and effectiveness in conducting thorough, science-based environmental reviews required to protect public health.
General description of the scientific conference activities:
The SETAC North America Annual Meeting was a five-day scientific conference bringing together a global community of environmental scientists, regulators, and researchers dedicated to the study, analysis, and solution of environmental problems. The meeting featured extensive training and learning opportunities, including more than 1,800 platform and poster presentations covering cutting-edge environmental research and applied science. Scientific sessions addressed topics related to environmental chemistry, toxicology, exposure assessment, risk analysis, and environmental fate and transport of chemicals. Attendees engaged with representatives from academia, business, and government to exchange scientific findings, discuss emerging methodologies, and review advances in environmental modeling and assessment tools. The conference also provided structured networking opportunities that supported collaboration and information-sharing among professionals working on environmental regulation, resource management, and environmental protection.
25. The American Association for Laboratory Animal Science 75th Annual Meeting
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Nashville, Tennessee
Conference Start Date: 11/03/2024
Conference End Date: 11/07/2024
Total FDA cost of the conference: $31,501.26
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 11
Explanation of how conference advanced the mission of FDA:
Attendance at The American Association for Laboratory Animal Science 75th Annual Meeting advanced the mission of FDA by strengthening the Agency’s scientific and regulatory expertise related to the ethical use, care, and management of laboratory animals in studies supporting regulatory review. Participation supported FDA’s responsibility to ensure that animal studies used in preclinical safety assessments are scientifically sound, ethically conducted, and appropriately designed to minimize animal use while generating reliable data. The conference enhanced FDA staff understanding of best practices in animal study and pathology study design, which are critical for accurate safety evaluation of regulated products. Engagement with subject-matter experts and stakeholders improved FDA’s ability to apply current regulatory considerations to animal studies and to communicate effectively with sponsors during the review process. Attendance also supported maintenance of critical occupational competencies and reinforced FDA initiatives related to animal welfare and scientific rigor, ultimately contributing to improved regulatory decision-making and protection of public health.
General description of the scientific conference activities:
The AALAS 75th Annual Meeting was the world’s largest professional gathering focused on the production, care, and use of laboratory animals. The conference featured expert-led scientific sessions addressing current practices in animal handling, management, and study design across multiple species. Presentations covered animal study design and pathology considerations within the regulatory framework, emphasizing ethical use of animals, minimization of repeat testing, and generation of high-quality data for regulatory review. The program included discussions on regulatory expectations for animal studies, challenges in pathology study design, and approaches for effective interaction with FDA during the review process. Attendees participated in educational sessions and professional exchanges that promoted best practices, enhanced scientific understanding, and supported continuous improvement in laboratory animal science and animal care.
26. American Biosafety Association International Conference
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Phoenix, Arizona
Conference Start Date: 11/01/2024
Conference End Date: 11/06/2024
Total FDA cost of the conference: $31,098.59
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 8
Explanation of how conference advanced the mission of FDA:
Attendance at the American Biosafety Association International Conference advanced FDA’s mission by strengthening the Agency’s capacity to oversee and improve biosafety, biosecurity, and laboratory safety programs that protect public health. Participation supported FDA’s responsibility to ensure safe handling of biological agents, compliance with biosafety and biosecurity regulations, and effective oversight of high-containment laboratories, including those involving select agents. The conference enhanced FDA staff knowledge of evolving biosafety practices, regulatory expectations, and occupational health considerations critical to maintaining safe research environments. Engagement with experts from federal agencies, academia, and industry supported information exchange, collaboration, and awareness of emerging risks and mitigation strategies. Attendance also supported maintenance of nationally recognized professional credentials and fulfillment of job-related requirements, ensuring FDA staff remained technically proficient and aligned with current best practices in biosafety and biosecurity.
General description of the scientific conference activities:
The ABSA International Conference was the largest global gathering focused on biosafety and biosecurity, featuring educational sessions, case studies, and discussions on current and emerging challenges in laboratory safety and biological risk management. The conference included scientific presentations addressing biosafety regulations, biosecurity laws, occupational health, and laboratory oversight, as well as poster sessions and interactive forums for professional exchange. Attendees participated in sessions highlighting best practices, new technologies, and regulatory developments relevant to biosafety program management. Commercial exhibits showcased the latest tools and innovations supporting biosafety and biosecurity operations. The conference also provided structured opportunities for networking and collaboration, enabling participants to discuss common challenges, share solutions, and explore potential partnerships across the scientific and regulatory community.
27. Consumer Electronic Showcase
Applicable Conference Type: Non-FDA Conference Attended by FDA
Conference Location: Las Vegas, Nevada
Conference Start Date: 01/07/2025
Conference End Date: 01/10/2025
Total FDA cost of the conference: $30,687.36
Total number of individuals whose travel expenses or other conference related expenses were paid by FDA: 9
Explanation of how conference advanced the mission of FDA:
Attendance at the Consumer Electronic Showcase advanced FDA’s mission by enhancing the Agency’s early awareness and understanding of emerging consumer and medical technologies that may intersect with FDA regulatory oversight. Participation allowed FDA staff to observe innovative prototypes and technologies prior to market release, supporting proactive consideration of potential safety, performance, and regulatory implications. The conference provided opportunities for outreach and dialogue with stakeholders to discuss regulatory requirements relevant to medical devices, digital health technologies, and global export considerations. Engagement at the event supported FDA’s ability to communicate its regulatory perspectives on health IT, artificial intelligence, and connected technologies while fostering collaboration with industry and technology developers. This early exposure to innovation trends supported informed regulatory planning and strengthened FDA’s readiness to address evolving technologies in support of public health.
General description of the scientific conference activities:
The Consumer Electronic Showcase was a large, international technology conference bringing together global brands, innovators, and industry leaders to present and demonstrate the latest advancements across multiple sectors, including digital health, artificial intelligence, cybersecurity, sustainability, and connected technologies. The conference featured immersive demonstrations, product unveilings, and presentations showcasing new and emerging technologies with potential applications to healthcare and medical devices. Attendees participated in discussions and networking opportunities focused on innovation trends, technology development, and future directions in health-related technologies. The event provided structured opportunities to engage with technology developers, explore practical applications of emerging tools, and gain insight into how technological advances may influence future product development and continuity across industries.